Literature DB >> 31369225

Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study

Diogo Cordeiro1, Zhiyuan Xu1, Gautam Mehta1, Dale Ding1, Mary Lee Vance1, Hideyuki Kano2, Nathaniel Sisterson2, Huai-che Yang2, Douglas Kondziolka2,3, L. Dade Lunsford2, David Mathieu4, Gene Barnett5, Veronica Chiang6, John Lee7, Penny Sneed8, Yan-Hua Su9, Cheng-chia Lee9, Michal Krsek10, Roman Liscak10, Ahmed Nabeel11, Amr El-Shehaby12, Khaled Karim12,13, Wael Reda12,13, Nuria Martinez-Moreno14, Roberto Martinez-Alvarez14, Kevin Blas15, Inga Grills15, Kuei Lee15, Mikulas Kosak16, Christopher Cifarelli17, Gennadiy Katsevman17, Jason Sheehan1.   

Abstract

OBJECTIVE: Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS.
METHODS: Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing’s disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6–246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism.
RESULTS: At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months. In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38).
CONCLUSIONS: Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies. © AANS, except where prohibited by US copyright law.

Entities:  

Keywords:  hypopituitarism; pituitary adenoma; Cushing’s disease; acromegaly; stereotactic radiosurgery

Year:  2018        PMID: 31369225      PMCID: PMC9535685          DOI: 10.3171/2018.5.JNS18509

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.408


  39 in total

1.  Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas -- a study on 721 patients.

Authors:  P Nomikos; C Ladar; R Fahlbusch; M Buchfelder
Journal:  Acta Neurochir (Wien)       Date:  2004-01-07       Impact factor: 2.216

2.  The stereotaxic method and radiosurgery of the brain.

Authors:  L LEKSELL
Journal:  Acta Chir Scand       Date:  1951-12-13

3.  Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus.

Authors:  Guenther Christian Feigl; Karin Pistracher; Andrea Berghold; Michael Mokry
Journal:  J Neurosurg       Date:  2010-12       Impact factor: 5.115

Review 4.  Stereotactic radiosurgery for pituitary tumors.

Authors:  Thomas C Witt
Journal:  Neurosurg Focus       Date:  2003-05-15       Impact factor: 4.047

5.  Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach.

Authors:  John A Jane; Mary Lee Vance; C J Woodburn; Edward R Laws
Journal:  Neurosurg Focus       Date:  2003-05-15       Impact factor: 4.047

Review 6.  Mortality in adults with hypopituitarism: a systematic review and meta-analysis.

Authors:  Sina Jasim; Fares Alahdab; Ahmed T Ahmed; Shrikant Tamhane; Larry J Prokop; Todd B Nippoldt; M Hassan Murad
Journal:  Endocrine       Date:  2016-11-05       Impact factor: 3.633

Review 7.  MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease.

Authors:  Susan M Webb; Iris Crespo; Alicia Santos; Eugenia Resmini; Anna Aulinas; Elena Valassi
Journal:  Eur J Endocrinol       Date:  2017-03-28       Impact factor: 6.664

Review 8.  Endocrine consequences of brain irradiation.

Authors:  A A Toogood
Journal:  Growth Horm IGF Res       Date:  2004-06       Impact factor: 2.372

Review 9.  Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.

Authors:  O M Dekkers; A M Pereira; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

10.  Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function.

Authors:  Gunther Christian Feigl; Christine Maria Bonelli; Andrea Berghold; Michael Mokry
Journal:  J Neurosurg       Date:  2002-12       Impact factor: 5.115

View more
  9 in total

1.  Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas.

Authors:  Natasha Ironside; Harrison Snyder; Zhiyuan Xu; David Schlesinger; Ching-Jen Chen; Mary Lee Vance; Gregory K Hong; John A Jane; Jason P Sheehan
Journal:  J Neurooncol       Date:  2022-04-24       Impact factor: 4.130

2.  Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section Part III: Lower cranial nerve schwannomas, jugular foramen (CN IX, X, XI) and hypoglossal schwannoma (XII).

Authors:  Jarnail Bal; Michael Bruneau; Moncef Berhouma; Jan F Cornelius; Luigi M Cavallo; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Torstein R Meling; Mahmoud Messerer; Pierre-Hugues Roche; Henry Schroeder; Marcos Tatagiba; Idoya Zazpe; Dimitrios Paraskevopoulos
Journal:  Acta Neurochir (Wien)       Date:  2021-12-02       Impact factor: 2.216

Review 3.  Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review.

Authors:  Adomas Bunevicius; Laura Donovan; Jason Sheehan
Journal:  J Neurooncol       Date:  2022-07-04       Impact factor: 4.506

4.  Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system.

Authors:  Nida Fatima; John H Shin; William T Curry; Steven D Chang; Antonio Meola
Journal:  J Neurooncol       Date:  2021-05-10       Impact factor: 4.130

5.  Upregulation of miR-499a-5p Decreases Cerebral Ischemia/Reperfusion Injury by Targeting PDCD4.

Authors:  Weifeng Shan; Huifeng Ge; Bingquan Chen; Linger Huang; Shaojun Zhu; Yanfeng Zhou
Journal:  Cell Mol Neurobiol       Date:  2021-04-09       Impact factor: 4.231

6.  Deep learning-based thin-section MRI reconstruction improves tumour detection and delineation in pre- and post-treatment pituitary adenoma.

Authors:  Da Hyun Lee; Ji Eun Park; Yeo Kyung Nam; Joonsung Lee; Seonok Kim; Young-Hoon Kim; Ho Sung Kim
Journal:  Sci Rep       Date:  2021-10-29       Impact factor: 4.379

Review 7.  Surgery for acromegaly: Indications and goals.

Authors:  David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-04       Impact factor: 6.055

Review 8.  Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases.

Authors:  Eric J Lehrer; Heather M McGee; Jason P Sheehan; Daniel M Trifiletti
Journal:  J Neurooncol       Date:  2020-02-12       Impact factor: 4.130

9.  Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up.

Authors:  Kerstin A Kessel; Christian D Diehl; Markus Oechsner; Bernhard Meyer; Jens Gempt; Claus Zimmer; Friederike Schmidt-Graf; Stephanie E Combs
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.